Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'INDINAVIR' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 567 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Skowron, G; Street, JC; Obee, EM
      Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    2. Servais, J; Nkoghe, T; Schmit, JC; Arendt, V; Robert, I; Staub, T; Moutschen, M; Schneider, F; Hemmer, R
      HIV-associated hematologic disorders are correlated with plasma viral loadand improve under highly active antiretroviral therapy

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    3. Lafeuillade, A; Poggi, C; Chadapaud, S; Hittinger, G; Chouraqui, M; Delbeke, E
      HIV-1 induction-maintenance at the lymph node level: The "Apollo-97" study

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    4. Dieleman, JP; Salahuddin, S; Hsu, YS; Burger, DM; Gyssens, IC; Sturkenboom, MCJM; Stricker, BHC; Kok, DJ
      Indinavir crystallization around the loop of Henle: Experimental evidence

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    5. Rakotoambinina, B; Medioni, J; Rabian, C; Jubault, V; Jais, JP; Viard, JP
      Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    6. Rey, D; Schmitt, MP; Partisani, M; Hess-Kempf, G; Krantz, W; de Mautort, E; Bernard-Henry, C; Priester, M; Cheneau, C; Lang, JM
      Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    7. Easterbrook, PJ; Newson, R; Ives, N; Pereira, S; Moyle, G; Gazzard, BG
      Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    8. Mole, L; Schmidgall, D; Holodniy, Y
      A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    9. Ungsedhapand, C; Kroon, EDMB; Suwanagool, S; Ruxrungtham, K; Yimsuan, N; Sonjai, A; Ubolyam, S; Buranapraditkun, S; Tiengrim, S; Pakker, N; Kunanusont, C; Lange, JMA; Cooper, DA; Phanuphak, P
      A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    10. Dube, MP; Edmondson-Melancon, H; Qian, D; Aqeel, R; Johnson, D; Buchanan, TA
      Prospective evaluation of the effect of initiating indinavir-based therapyon insulin sensitivity and B-cell function in HIV-infected patients

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    11. Becker, S; Fisher, A; Flexner, C; Gerber, JG; Haubrich, R; Kashuba, ADM; Luber, AD; Piscitelli, SC
      Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio:Call for consensus

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    12. Eron, JJ; Haubrich, R; Lang, W; Pagano, G; Millard, J; Wolfram, J; Snowden, W; Pedneault, L; Tisdale, M
      A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    13. Pezzotti, P; Pappagallo, M; Phillips, PN; Boros, S; Valdarchi, C; Sinicco, A; Zaccarelli, M; Rezza, G
      Response to highly active antiretroviral therapy according to duration of HIV infection

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    14. Kost, RG; Hurley, A; Zhang, LQ; Vesanen, M; Talal, A; Furlan, S; Caldwell, P; Johnson, J; Smiley, L; Ho, D; Markowitz, M
      Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1-infected patients

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    15. Burger, DM; Hugen, PWH; Aarnoutse, RE; Dieleman, JP; Prins, JM; van der Poll, T; ten Veen, JH; Mulder, JW; Meenhorst, PL; Blok, WL; van der Meer, JTM; Reiss, P; Lange, JMA
      A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: Pharmacokinetics, safety, and efficacy

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    16. Hansel, A; Bucher, HC; Nuesch, R; Battegay, H
      Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients

      JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    17. Aarnoutse, RE; Wissen, CPWGMVV; Underberg, WJM; Kleinnijenhuis, J; Hekster, YA; Burger, DM
      High-performance liquid chromatography of HIV protease inhibitors in humanbiological matrices

      JOURNAL OF CHROMATOGRAPHY B
    18. Dailly, E; Thomas, L; Kergueris, MF; Jolliet, P; Bourin, M
      High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavirand saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction

      JOURNAL OF CHROMATOGRAPHY B
    19. Sarasa-Nacenta, M; Lopez-Pua, Y; Mallolas, J; Blanco, JL; Gatell, JM; Carne, X
      Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    20. Yamada, H; Kotaki, H; Nakamura, T; Iwamoto, A
      Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    21. Langmann, P; Schirmer, D; Vath, T; Zilly, M; Klinker, H
      High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy

      JOURNAL OF CHROMATOGRAPHY B
    22. Mijch, AM; Hoy, J; Watson, K; Dunne, A; Crowe, S; Wesselingh, SL
      Does plasma HIV RNA predict outcome in a cohort of treated HIV-infected individuals followed over 3 years?

      JOURNAL OF CLINICAL VIROLOGY
    23. Nieuwkerk, P; Gisolf, E; Sprangers, M; Danner, S
      Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response

      ANTIVIRAL THERAPY
    24. McMahon, D; Lederman, M; Haas, DW; Haubrich, R; Stanford, J; Cooney, E; Horton, J; Kelleher, D; Ross, L; Cutrell, A; Lee, D; Spreen, W; Mellors, JW
      Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults

      ANTIVIRAL THERAPY
    25. Gartland, M
      AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients

      ANTIVIRAL THERAPY
    26. Rozenbaum, W; Katlama, C; Massip, P; Bentata, M; Zucman, D; Delfraissy, JF; Trepo, C; David, F; Lanier, ER; Vavro, C; Mamet, JP
      Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment

      ANTIVIRAL THERAPY
    27. Kollmann, C; Tremblay, C; Giguel, F; Chou, TC; Hirsch, MS
      In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz

      ANTIVIRAL THERAPY
    28. Hoetelmans, R
      Pharmacological exposure and the development of drug resistance in HIV

      ANTIVIRAL THERAPY
    29. Plosker, GL; Perry, CM; Goa, KL
      Efavirenz - A pharmacoeconomic review of its use in HIV infection

      PHARMACOECONOMICS
    30. Knobel, H; Guelar, A; Carmona, A; Espona, M; Gonzalez, A; Lopez-Colomes, JL; Saballs, P; Gimeno, JL; Diez, A
      Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors

      AIDS PATIENT CARE AND STDS
    31. Collazos, J; Mayo, J; Martinez, E
      The evolving mode of presentation of HIV-infected patients to health services of Northern Spain: 1985 through December 1999

      AIDS PATIENT CARE AND STDS
    32. Blower, SM; Aschenbach, AN; Gershengorn, HB; Kahn, JO
      Predicting the unpredictable: Transmission of drug-resistant HIV

      NATURE MEDICINE
    33. Stoddart, CA; Liegler, TJ; Mammano, F; Linquist-Stepps, VD; Hayden, MS; Deeks, SG; Grant, RM; Clavel, F; McCune, JM
      Impaired replication of protease inhibitor-resistant HIV-1 in human thymus

      NATURE MEDICINE
    34. James, CW; McNelis, KC; Cohen, DM; Szabo, S; Bincsik, AK
      Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy

      ANNALS OF PHARMACOTHERAPY
    35. John, L; Marra, F; Ensom, MHH
      Role of therapeutic drug monitoring for protease inhibitors

      ANNALS OF PHARMACOTHERAPY
    36. Manfredi, R; Calza, L; Chiodo, F
      Gynecomastia associated with highly active antiretroviral therapy

      ANNALS OF PHARMACOTHERAPY
    37. Rayner, CR; Esch, LD; Wynn, HE; Eales, R
      Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen

      ANNALS OF PHARMACOTHERAPY
    38. Benveniste, O; Simon, A; Herson, S
      Successful percutaneous dihydrotestosterone treatment of gynecomastia occurring during highly active antiretroviral therapy: Four cases and a review of the literature

      CLINICAL INFECTIOUS DISEASES
    39. Jenny-Avital, ER
      Protease inhibitors and rifabutin: Isn't the jury still out?

      CLINICAL INFECTIOUS DISEASES
    40. Narita, M; Stambaugh, JJ; Hollender, ES; Pitchenik, AE; Ashkin, D
      Protease inhibitors and rifabutin: Isn't the jury still out? Reply

      CLINICAL INFECTIOUS DISEASES
    41. Valdez, H; Chowdhry, TK; Asaad, R; Woolley, IJ; Davis, T; Davidson, R; Beinker, N; Gripshover, BM; Salata, RA; McComsey, G; Weissman, SB; Lederman, MM
      Changing spectrum of mortality due to human immunodeficiency virus: Analysis of 260 deaths during 1995-1999

      CLINICAL INFECTIOUS DISEASES
    42. Richert, B
      Frictional pyogenic granuloma of the nail bed

      DERMATOLOGY
    43. Vergis, EN; Paterson, DL; Wagener, MM; Swindells, S; Singh, N
      Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy

      INTERNATIONAL JOURNAL OF STD & AIDS
    44. Nouts, C; Bonarek, M; Morlat, P; Delevaux, I; Bonnet, F; Lacoste, D; Bernard, N; Beylot, J
      The absence of hyperbilirubinaemia is highly predictive of treatment failure in advanced HIV-infected patients treated with indinavir

      INTERNATIONAL JOURNAL OF STD & AIDS
    45. Walli, R; Michl, GM; Bogner, JR; Goebel, FD
      Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir

      EUROPEAN JOURNAL OF MEDICAL RESEARCH
    46. Penzak, SR; Lawhorn, WD; Gubbins, PO
      Rapid and sensitive high-performance liquid chromatographic method for thedetermination of ritonavir in human plasma

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    47. Capparelli, EV; Sullivan, JL; Mofenson, L; Smith, E; Graham, B; Britto, P; Becker, MI; Holland, D; Connor, JD; Luzuriaga, K
      Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants

      PEDIATRIC INFECTIOUS DISEASE JOURNAL
    48. Kline, MW; Brundage, RC; Fletcher, CV; Schwarzwald, H; Calles, NR; Buss, NE; Snell, P; Delora, P; Eason, M; Jorga, K; Craig, C; Duff, F
      Combination therapy with saquinavir soft gelatin capsules in children withhuman immunodeficiency virus infection

      PEDIATRIC INFECTIOUS DISEASE JOURNAL
    49. Kling, J
      Hot papers - CD4(+) T cell mechanism allows HIV-1 persistence - Comment

      SCIENTIST
    50. Kaufmann, GR; Zaunders, J; Murray, J; Kelleher, AD; Lewin, SR; Solomon, A; Smith, D; Cooper, DA
      Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    51. Fitzgibbon, JE; Gaur, S; Walsman, SM; Janahi, M; Whitley-Williams, P; John, JF
      Emergence of drug resistance mutations in a group of HIV-infected childrentaking nelfinavir-containing regimens

      AIDS RESEARCH AND HUMAN RETROVIRUSES
    52. Bani-Sadr, F; Teissiere, F; Curie, I; Bernard, L; Melchior, JC; Brion, F; Durigon, M; Perronne, C; de Truchis, P
      Anti-infection prophylaxis after sexual assault: experience at the RaymondPoincare Garches Hospital

      PRESSE MEDICALE
    53. Reliquet, V; Robillard, N; Perre, P; Muller, JY; Raffi, F; Audrain, M
      Immune response to antiretroviral treatment combining stavudine, didanosine and nevirapine

      PRESSE MEDICALE
    54. Meynard, JL; Guiguet, M; Rachline, A; Boukli, N; Bollens, D; Gentil, C; Frottier, J; Morand-Joubert, L
      Factors predicting response to antiretroviral regimens with a protease inhibitor in HIV-infected subjects

      PRESSE MEDICALE
    55. DeMasi, RA; Graham, NM; Tolson, JM; Pham, SV; Capuano, GA; Fisher, RL; Shaefer, MS; Pakes, GE; Sawyerr, GA; Eron, JJ
      Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome

      ADVANCES IN THERAPY
    56. Jayewardene, AL; Kearney, B; Stone, JA; Gambertoglio, JG; Aweeka, FT
      An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    57. Nakamura, M; Terada, M; Matsuzaki, K; Yoshida, K; Ohno, T
      Mechanism of inhibitory effect of NCC164 on replication of human immunodeficiency virus

      MICROBIOLOGY AND IMMUNOLOGY
    58. Gekker, G; Lokensgard, JR; Peterson, PK
      Naltrexone potentiates anti-HIV-1 activity of antiretroviral drugs in CD4(+) lymphocyte cultures

      DRUG AND ALCOHOL DEPENDENCE
    59. Garrait, V; Molina, JM
      New strategies for antiretroviral treatment in HIV-infected patients.

      PATHOLOGIE BIOLOGIE
    60. Bournique, B; Lambert, N; Boukaiba, R; Martinet, M
      In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine 1-carboxamide)

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    61. Back, DJ; Khoo, SH; Gibbons, SE; Merry, C
      The role of therapeutic drug monitoring in treatment of HIV infection

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    62. Back, DJ; Khoo, SH; Gibbons, SE; Merry, C
      The role of therapeutic drug monitoring in treatment of HIV infection

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    63. Dieleman, JP; van der Feltz, M; Bangma, CH; Stricker, BHC; van der Ende, ME
      Papillary necrosis associated with the HIV protease inhibitor indinavir

      INFECTION
    64. Temple, ME; Koranyi, KI; Nahata, MC
      The safety and antiviral effect of protease inhibitors in children

      PHARMACOTHERAPY
    65. Reilly, RF; Tray, K; Perazella, MA
      Indinavir nephropathy revisited: A pattern of insidious renal failure withidentifiable risk factors

      AMERICAN JOURNAL OF KIDNEY DISEASES
    66. Szczech, LA
      Hypertension and medication-related renal dysfunction in the HIV-infected patient

      SEMINARS IN NEPHROLOGY
    67. Di Martino, V; Rufat, P; Boyer, N; Renard, P; Degos, F; Martinot-Peignoux, M; Matheron, S; Le Moing, V; Vachon, F; Degott, C; Valla, D; Marcellin, P
      The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study

      HEPATOLOGY
    68. Benhamou, Y; Di Martino, V; Bochet, M; Colombet, G; Thibault, V; Liou, A; Katlama, C; Poynard, T
      Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy

      HEPATOLOGY
    69. Ghani, AC; Henley, WE; Donnelly, CA; Mayer, S; Anderson, RM
      Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases

      AIDS
    70. Sadler, BM; Piliero, PJ; Preston, SL; Lloyd, PP; Lou, Y; Stein, DS
      Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

      AIDS
    71. Duran, S; Solas, C; Spire, B; Carrieri, MP; Fuzibet, JG; Costagliola, D; Lacarelle, B; Moatti, JP
      'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports andserum protease inhibitor concentrations in the French Manif 2000 cohort study

      AIDS
    72. Noor, MA; Lo, JC; Mulligan, K; Schwarz, JM; Halvorsen, RA; Schambelan, M; Grunfeld, C
      Metabolic effects of indinavir in healthy HIV-seronegative men

      AIDS
    73. Tebas, P; Henry, K; Nease, R; Murphy, R; Phair, J; Powderly, WG
      Timing of antiretroviral therapy. Use of Markov modeling and decision analysis to evaluate the long-term implications of therapy

      AIDS
    74. Kemper, CA; Witt, MD; Keiser, PH; Dube, MP; Forthal, DN; Leibowitz, M; Smith, DS; Rigby, A; Hellmann, NS; Lie, YS; Leedom, J; Richman, D; McCutchan, JA; Haubrich, R
      Sequencing of protease inhibitor therapy: insights from an analysis of HIVphenotypic resistance in patients failing protease inhibitors

      AIDS
    75. van der Sandt, ICJ; Vos, CMP; Nabulsi, L; Blom-Roosemalen, MCM; Voorwinden, HH; de Boer, AG; Breimer, DD
      Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier

      AIDS
    76. Detels, R; Tarwater, P; Phair, JP; Margolick, J; Riddler, SA; Munoz, A
      Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis

      AIDS
    77. Liegler, TJ; Hayden, MS; Lee, KH; Hoh, R; Deeks, SG; Grant, RM
      Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes

      AIDS
    78. Mocroft, A; Youle, M; Moore, A; Sabin, CA; Madge, S; Lepri, AC; Tyrer, M; Chaloner, C; Wilson, D; Loveday, C; Johnson, MA; Phillips, AN
      Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre

      AIDS
    79. Grant, LA; Silverberg, MJ; Palacio, H; Minkoff, H; Anastos, K; Young, MA; Nowicki, M; Kovacs, A; Cohen, M; Munoz, A
      Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels

      AIDS
    80. Landau, A; Batisse, D; Piketty, C; Van Huyen, LPD; Bloch, F; Belec, L; Bruneval, P; Weiss, L; Jian, R; Kazatchkine, MD
      Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

      AIDS
    81. Saag, MS; Tebas, P; Sension, M; Conant, M; Myers, R; Chapman, SK; Anderson, R; Clendeninn, N
      Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)

      AIDS
    82. Toma, E; Devost, D; Lan, NC; Bhat, PV
      HIV-protease inhibitors alter retinoic acid synthesis

      AIDS
    83. Carr, A; Hudson, J; Chuah, J; Mallal, S; Law, M; Hoy, J; Doong, N; French, M; Smith, D; Cooper, DA
      HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

      AIDS
    84. Lew, E; Gallagher, L; Kuehnert, M; Rimland, D; Hubbard, M; Parekh, B; Zell, E; Jarvis, W; Jason, J
      Intracellular cytokines in the acute response to highly active antiretroviral therapy

      AIDS
    85. Gallego, O; de Mendoza, C; Perez-Elias, MJ; Guardiola, JM; Pedreira, J; Dalmau, D; Gonzalez, J; Moreno, A; Arribas, JR; Rubio, A; Garcia-Arata, I; Leal, M; Domingo, P; Soriano, V
      Drug resistance in patients experiencing early virological failure under atriple combination including indinavir

      AIDS
    86. Celentano, DD; Galai, N; Sethi, AK; Shah, NG; Strathdee, SA; Vlahov, D; Gallant, JE
      Time to initiating highly active antiretroviral therapy among HIV infectedinjection drug users

      AIDS
    87. Martinez, E; Arnedo, M; Giner, V; Gil, C; Caballero, M; Alos, L; Garcia, F; Holtzer, C; Mallolas, J; Miro, JM; Pumarola, T; Gatell, JM
      Lymphoid tissue viral burden and duration of viral suppression in plasma

      AIDS
    88. Clumeck, N; Goebel, F; Rozenbaum, W; Gerstoft, J; Staszewski, S; Montaner, J; Johnson, M; Gazzard, B; Stone, C; Athisegaran, R; Moore, S
      Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA

      AIDS
    89. Bartlett, JA; DeMasi, R; Quinn, J; Moxham, C; Rousseau, F
      Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

      AIDS
    90. Havlir, DV; Gilbert, PB; Bennett, K; Collier, AC; Hirsch, MS; Tebas, P; Adams, EM; Wheat, LJ; Goodwin, D; Schnittman, S; Holohan, MK; Richman, DD
      Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

      AIDS
    91. Nolan, D; Upton, R; McKinnon, E; John, M; James, I; Adler, B; Roff, C; Vasikaran, S; Mallal, S
      Stable or increasing bone mineral density in HIV-infected patients treatedwith nelfinavir or indinavir

      AIDS
    92. Murphy, RL; Brun, S; Hicks, C; Eron, JT; Gulick, R; King, M; White, AC; Benson, C; Thompson, M; Kessler, HA; Hammer, S; Bertz, R; Hsu, A; Japour, A; Sun, E
      ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

      AIDS
    93. Mercie, P; Viallard, JF; Thiebaut, R; Faure, I; Rispal, P; Leng, B; Pellegrin, JL
      Efavirenz-associated breast hypertrophy in HIV-infected patients

      AIDS
    94. Bossi, P; Martinez, V; Strady, C; Bricaire, F
      Antiretroviral treatments in 2000

      REVUE DE MEDECINE INTERNE
    95. Camino, X; Iribarren, JA; Arrizabalaga, J; Rodriguez, F; von Wichmann, MA
      Causes of mortality among patients infected with the human immunodeficiency virus in the era of highly active antiretroviral therapy

      ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
    96. Smeaton, LM; DeGruttola, V; Robbins, GK; Shafer, RW
      ACTG (AIDS Clinical Trials Group) 384: A strategy trial comparing consecutive treatments for HIV-1

      CONTROLLED CLINICAL TRIALS
    97. Babiker, AG; Darbyshire, JH; Cooper, DA; Hooker, MH; Withnall, R; Yeni, P
      An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methodsof the initio trial

      CONTROLLED CLINICAL TRIALS
    98. Filippi, CG; Ulug, AM; Ryan, E; Ferrando, SJ; van Gorp, W
      Diffusion tensor imaging of patients with HIV and normal-appearing white matter on MR images of the brain

      AMERICAN JOURNAL OF NEURORADIOLOGY
    99. Johanson, J; Abravaya, K; Caminiti, W; Erickson, D; Flanders, R; Leckie, G; Marshall, E; Mullen, C; Ohhashi, Y; Perry, R; Ricci, J; Salituro, J; Smith, A; Tang, N; Vi, M; Robinson, J
      A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma

      JOURNAL OF VIROLOGICAL METHODS
    100. Carbonara, S; Fiorentino, G; Serio, G; Maggi, P; Ingravallo, G; Monno, L; Bruno, F; Coppola, S; Pastore, G; Angarano, G
      Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors

      JOURNAL OF INFECTION


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/02/20 alle ore 18:05:38